{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:59:04Z","timestamp":1794203944622,"version":"4.8.0"},"reference-count":18,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cellestia Biotech"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,14]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>CB-103 selectively inhibits the CSL\u2013NICD (Notch intracellular domain) interaction leading to transcriptional downregulation of oncogenic Notch pathway activation. This dose-escalation\/expansion study aimed to determine safety, pharmacokinetics, and preliminary antitumor activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Patients \u226518 years of age with selected advanced solid tumors [namely, adenoid cystic carcinoma (ACC)] and hematologic malignancies were eligible. CB-103 was dosed orally in cycles of 28 days at escalating doses until disease progression. Notch-activating mutations were required in a dose confirmatory cohort. Endpoints included dose-limiting toxicities (DLT), safety, tumor response, pharmacokinetics, and pharmacodynamics. Exploratory analyses focused on correlates of Notch and target gene expression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Seventy-nine patients (64, 12 dose-escalation cohorts; 15, confirmatory cohort) enrolled with 54% receiving two or more lines of prior therapy. ACC was the dominant tumor type (40, 51%). Two DLTs were observed [elevated gamma-glutamyl transferase (GGT), visual change]; recommended phase II dose was declared as 500 mg twice daily (5 days on, 2 days off weekly). Grade 3\u20134 treatment-related adverse events occurred in 15 patients (19%), including elevated liver function tests (LFTs), anemia, and visual changes. Five (6%) discontinued drug for toxicity; with no drug-related deaths. There were no objective responses, but 37 (49%) had stable disease; including 23 of 40 (58%) patients with ACC. In the ACC cohort, median progression-free survival was 2.5 months [95% confidence interval (CI), 1.5\u20133.7] and median overall survival was 18.4 months (95% CI, 6.3\u2013not reached).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>CB-103 had a manageable safety profile and biological activity but limited clinical antitumor activity as monotherapy in this first-in-human study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>CB-103 is a novel oral pan-Notch inhibitor that selectively blocks the CSL\u2013NICD interaction leading to transcriptional downregulation of oncogenic Notch pathway activation. This first-in-human dose-escalation and -confirmation study aimed to determine the safety, pharmacokinetics, and preliminary antitumor efficacy of CB-103. We observed a favorable safety profile with good tolerability and biological activity but limited clinical single-agent antitumor activity. Some disease stabilization was observed among an aggressive NOTCH-mutant ACC type-I subgroup where prognosis is poor and therapies are critically needed. Peripheral downregulation of select Notch target gene levels was observed with escalating doses. Future studies exploring CB-103 should enrich for patients with NOTCH-mutant ACC and investigate rational combinatorial approaches in tumors where there is limited success with investigational or approved drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0333","type":"journal-article","created":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T09:37:20Z","timestamp":1692783440000},"page":"1853-1861","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9969-2523","authenticated-orcid":true,"given":"Glenn J.","family":"Hanna","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Center for Head and Neck Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2859-7529","authenticated-orcid":true,"given":"Anastasios","family":"Stathis","sequence":"additional","affiliation":[{"name":"2Oncology Institute of Southern Switzerland, EOC, Bellinzona, Switzerland."},{"name":"3Faculty of Biomedical Sciences, Universit\u00e0 della Svizzera Italiana (USI), Lugano, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2253-739X","authenticated-orcid":true,"given":"Elena","family":"Lopez-Miranda","sequence":"additional","affiliation":[{"name":"4Medical Oncology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1502-6989","authenticated-orcid":true,"given":"Fabricio","family":"Racca","sequence":"additional","affiliation":[{"name":"5IOB \u2013 Institute of Oncology Barcelona and Madrid, Hospital Quironsalud-Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9148-3268","authenticated-orcid":true,"given":"Doris","family":"Quon","sequence":"additional","affiliation":[{"name":"6Sarcoma Oncology Research Center, Santa Monica, California."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5705-6799","authenticated-orcid":true,"given":"Serge","family":"Leyvraz","sequence":"additional","affiliation":[{"name":"7Charit\u00e9 Comprehensive Cancer Center, Charit\u00e9 Campus Benjamin Franklin, Berlin, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4993-8744","authenticated-orcid":true,"given":"Dagmar","family":"Hess","sequence":"additional","affiliation":[{"name":"8Department of Medical Oncology, Kantonsspital St Gallen, St Gallen, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8196-4247","authenticated-orcid":true,"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[{"name":"9Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6467-3632","authenticated-orcid":true,"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[{"name":"10Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9654","authenticated-orcid":true,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"11Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, Republic of South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1842-9070","authenticated-orcid":true,"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[{"name":"12Severance Hospital \u2013 Yonsei Cancer Center, Seoul, Republic of South Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-4512","authenticated-orcid":true,"given":"Andreas","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"13National Center for Tumor Diseases (NCT), University Hospital Heidelberg and German Cancer Research Center, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-6024","authenticated-orcid":true,"given":"Josep-Maria","family":"Ribera","sequence":"additional","affiliation":[{"name":"14Institut Catal\u00e0 d'Oncologia (Catalan Institute of Oncology [ICO]), Josep Carreras Research Institute, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7865-2306","authenticated-orcid":true,"given":"Daniel","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"15Division of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Manuel","family":"Perez Garcia","sequence":"additional","affiliation":[{"name":"16International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Hospital, Barcelona, Spain."},{"name":"17Medica Scientia Innovation Research, Barcelona, Spain."},{"name":"18Medica Scientia Innovation Research, Ridgewood, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":true,"given":"Javier","family":"Cortes","sequence":"additional","affiliation":[{"name":"16International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Hospital, Barcelona, Spain."},{"name":"17Medica Scientia Innovation Research, Barcelona, Spain."},{"name":"18Medica Scientia Innovation Research, Ridgewood, New Jersey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5266-7881","authenticated-orcid":true,"given":"Oliver","family":"Sch\u00f6nborn-Kellenberger","sequence":"additional","affiliation":[{"name":"19Cogitars GmbH, Heidelberg, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1562-3273","authenticated-orcid":true,"given":"Dirk","family":"Weber","sequence":"additional","affiliation":[{"name":"20Cellestia Biotech AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1837-3846","authenticated-orcid":true,"given":"Pavel","family":"Pisa","sequence":"additional","affiliation":[{"name":"21piMedConsulting Ltd, Gersau, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4193-2731","authenticated-orcid":true,"given":"Michael","family":"Bauer","sequence":"additional","affiliation":[{"name":"20Cellestia Biotech AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1336-6165","authenticated-orcid":true,"given":"Laura","family":"Beni","sequence":"additional","affiliation":[{"name":"20Cellestia Biotech AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2295-8702","authenticated-orcid":true,"given":"Maria","family":"Bobadilla","sequence":"additional","affiliation":[{"name":"20Cellestia Biotech AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9508-7553","authenticated-orcid":true,"given":"Raj","family":"Lehal","sequence":"additional","affiliation":[{"name":"20Cellestia Biotech AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4765-6598","authenticated-orcid":true,"given":"Michele","family":"Vigolo","sequence":"additional","affiliation":[{"name":"22R&D, Cellestia Biotech AG, Epalinges, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1480-4784","authenticated-orcid":true,"given":"Florian D.","family":"Vogl","sequence":"additional","affiliation":[{"name":"20Cellestia Biotech AG, Basel, Switzerland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4412-7842","authenticated-orcid":true,"given":"Elena","family":"Garralda","sequence":"additional","affiliation":[{"name":"23Early Drug Development Unit, Clinical Research Program, Vall d'Hebron University Hospital and Institute of Oncology (VHIO) and Medical Oncology, Vall d'Hebron University Hospital (HUVH), Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"2023091414052531700_bib1","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1038\/onc.2008.223","article-title":"More complicated than it looks: assembly of Notch pathway transcription complexes","volume":"27","author":"Kovall","year":"2008","journal-title":"Oncogene"},{"key":"2023091414052531700_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccr.2014.02.018","article-title":"From fly wings to targeted cancer therapies: a centennial for notch signaling","volume":"25","author":"Ntziachristos","year":"2014","journal-title":"Cancer Cell"},{"key":"2023091414052531700_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0092-8674(87)90667-2","article-title":"Analysis of DNA surrounding the breakpoints of chromosomal translocations involving the beta T cell receptor gene in human lymphoblastic neoplasms","volume":"50","author":"Reynolds","year":"1987","journal-title":"Cell"},{"key":"2023091414052531700_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","article-title":"The varied roles of notch in cancer","volume":"12","author":"Aster","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"2023091414052531700_bib5","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrc3035","article-title":"Notch signalling in solid tumours: a little bit of everything but not all the time","volume":"11","author":"Ranganathan","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2023091414052531700_bib6","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1172\/JCI128227","article-title":"Genetic hallmarks of recurrent\/metastatic adenoid cystic carcinoma","volume":"129","author":"Ho","year":"2019","journal-title":"J Clin Invest"},{"key":"2023091414052531700_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JCO.2016.67.5264","article-title":"Activating NOTCH1 mutations define a distinct subgroup of patients with adenoid cystic carcinoma who have poor prognosis, propensity to bone and liver metastasis, and potential responsiveness to notch1 inhibitors","volume":"35","author":"Ferrarotto","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023091414052531700_bib8","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nrd4252","article-title":"Therapeutic modulation of Notch signalling\u2013are we there yet?","volume":"13","author":"Andersson","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2023091414052531700_bib9","doi-asserted-by":"crossref","first-page":"16292","DOI":"10.1073\/pnas.1922606117","article-title":"Pharmacological disruption of the Notch transcription factor complex","volume":"117","author":"Lehal","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023091414052531700_bib10","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1200\/JCO.2007.12.1012","article-title":"Translation of innovative designs into phase I trials","volume":"25","author":"Rogatko","year":"2007","journal-title":"J Clin Oncol"},{"key":"2023091414052531700_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.6046","article-title":"Results of ACCURACY: a phase 2 trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent\/metastatic (R\/M) adenoid cystic carcinoma (ACC) harboring Notch activating mutations (Notchmut)","volume":"40","author":"Ferrarotto","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023091414052531700_bib12","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.18.01859","article-title":"Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma","volume":"37","author":"Tchekmedyian","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023091414052531700_bib13","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1002\/cncr.32754","article-title":"Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: activity and quality of life","volume":"126","author":"Locati","year":"2020","journal-title":"Cancer"},{"key":"2023091414052531700_bib14","doi-asserted-by":"crossref","first-page":"5272","DOI":"10.1158\/1078-0432.CCR-21-1061","article-title":"Randomized phase II study of axitinib versus observation in patients with recurred or metastatic adenoid cystic carcinoma","volume":"27","author":"Kang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023091414052531700_bib15","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/1078-0432.CCR-20-1192","article-title":"Proteogenomic analysis of salivary adenoid cystic carcinomas defines molecular subtypes and identifies therapeutic targets","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023091414052531700_bib16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bcmd.2007.05.007","article-title":"Revisiting a selection of target genes for the hematopoietic transcription factor c-Myb using chromatin immunoprecipitation and c-Myb knockdown","volume":"39","author":"Berge","year":"2007","journal-title":"Blood Cells Mol Dis"},{"key":"2023091414052531700_bib17","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1158\/1535-7163.MCT-10-0372","article-title":"Combined inhibition of Notch signaling and Bcl-2\/Bcl-xL results in synergistic antimyeloma effect","volume":"9","author":"Li","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2023091414052531700_bib18","doi-asserted-by":"crossref","first-page":"6885","DOI":"10.18632\/oncotarget.2321","article-title":"NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma","volume":"5","author":"Su","year":"2014","journal-title":"Oncotarget"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0333\/3359607\/crc-23-0333.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1853\/3364187\/crc-23-0333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/9\/1853\/3364187\/crc-23-0333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T13:16:37Z","timestamp":1729948597000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/9\/1853\/729041\/A-Phase-I-Study-of-the-Pan-Notch-Inhibitor-CB-103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9,14]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0333","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24139142.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139136.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139148","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139133.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139136","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139124","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139139.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139154","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139142","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139130","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139145.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139148.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139154.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139151.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139139","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139127","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139145","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139133","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139121","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139151","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139124.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139130.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139121.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24139127.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6835166.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6835166","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,14]]}}}